Trazodone

Exact current instruction and Georgian veterinary registrations verify identity, strengths, species and dose tables. Independent exact-formulation evidence and internationally recognised exact-product authorisation remain limited.

Randomised canine studies support trazodone for veterinary-visit and travel stress at broadly comparable active exposure, but the exact succinate formulation and every broad label scenario lack strong independent replication.

Canine single-dose evidence is reasonably reassuring, but sedation, ataxia and examination changes are expected possibilities; serotonergic, cardiovascular, seizure, organ-disease and reproductive restrictions remain clinically important.

A palatable scored tablet and one pre-event dose are practical, but half-tablet steps create coarse exposure at low weights and food timing plus possible redosing require a written plan.

Exact current instruction and Georgian veterinary registrations verify identity, strengths, species and dose tables. Independent exact-formulation evidence and internationally recognised exact-product authorisation remain limited.

A small feline crossover trial supports pre-visit trazodone, but a 2025 review judged the overall evidence weak; the exact succinate product relies mainly on sponsor-linked studies and its base-equivalent dose is below the best-known 50 mg trial in many cats.

Single-dose feline studies are generally reassuring but small; sedation, ataxia or paradoxical agitation remain possible, while exact-label exclusions cover cardiovascular disease, epilepsy, organ dysfunction, pregnancy, lactation and neonates.

A palatable scored tablet and one pre-event dose are practical, but half-tablet steps create coarse exposure at low weights and food timing plus possible redosing require a written plan.

Exact current instruction and Georgian veterinary registrations verify identity, strengths, species and dose tables. Independent exact-formulation evidence and internationally recognised exact-product authorisation remain limited.

Randomised canine studies support trazodone for veterinary-visit and travel stress at broadly comparable active exposure, but the exact succinate formulation and every broad label scenario lack strong independent replication.

Canine single-dose evidence is reasonably reassuring, but sedation, ataxia and examination changes are expected possibilities; serotonergic, cardiovascular, seizure, organ-disease and reproductive restrictions remain clinically important.

One scored palatable tablet strength covers the label’s medium/large-dog bands and is given 60 minutes before the event; half-tablet steps and the over-40 kg rule still require exact weight-based selection.

The exact human drops are identifiable in a current regulator SPC and EU authorisation data; the 60 mg/ml form is also currently registered in Georgia, while the 25 mg/ml form is not. Veterinary use is off-label and the species studies used immediate-release oral trazodone rather than these exact liquid presentations.

Randomised controlled trials show meaningful reductions in selected stress and anxiety behaviours during veterinary visits, travel and shelter care, and observational evidence supports hospital use. Outcomes are not uniformly positive across every behaviour or postsurgical-confinement study, so it is a useful situational adjunct rather than a universally reliable sedative.

Oral veterinary studies generally found acceptable short-course tolerability, but sedation, ataxia, gastrointestinal effects, paradoxical excitation, tachycardia or hypotension and rare priapism remain relevant. Serotonin syndrome, additive CNS depression and QT-risk interactions require medication review; evidence is mostly from healthy or selected dogs.

The lower-concentration liquid can improve dose titration for small patients and those unable to take tablets, but the exact measuring device, mg-to-ml conversion and human-formulation excipients must be checked. A supervised trial dose and trigger-based timing remain necessary.

The exact human drops are identifiable in a current regulator SPC and EU authorisation data; the 60 mg/ml form is also currently registered in Georgia, while the 25 mg/ml form is not. Veterinary use is off-label and the species studies used immediate-release oral trazodone rather than these exact liquid presentations.

Small randomised studies support sedation and reduced transport/examination anxiety, including positive 50 mg and 5 mg/kg trials. Other small work found no examination-behaviour advantage at the tested time point, and current feline guidelines describe the evidence as conflicting; benefit is plausible but less secure than in dogs.

Small feline studies generally found sedation without serious short-term events, but they cannot define uncommon-event, repeated-use, geriatric, organ-disease or reproductive safety. Sedation, ataxia, gastrointestinal effects, cardiovascular change and serotonin syndrome remain relevant, especially with other serotonergic or CNS-depressant drugs.

The lower-concentration liquid can improve dose titration for small patients and those unable to take tablets, but the exact measuring device, mg-to-ml conversion and human-formulation excipients must be checked. A supervised trial dose and trigger-based timing remain necessary.

The exact human immediate-release tablet is identifiable in a current regulator SPC and EU authorisation data; the 50 mg and 100 mg forms are not currently registered in Georgia. Veterinary use is off-label, but multiple species-specific controlled studies and professional guidelines support the active ingredient and route.

Randomised controlled trials show meaningful reductions in selected stress and anxiety behaviours during veterinary visits, travel and shelter care, and observational evidence supports hospital use. Outcomes are not uniformly positive across every behaviour or postsurgical-confinement study, so it is a useful situational adjunct rather than a universally reliable sedative.

Oral veterinary studies generally found acceptable short-course tolerability, but sedation, ataxia, gastrointestinal effects, paradoxical excitation, tachycardia or hypotension and rare priapism remain relevant. Serotonin syndrome, additive CNS depression and QT-risk interactions require medication review; evidence is mostly from healthy or selected dogs.

A scored 50 mg tablet is easy to dispense and closely matches common single-dose study regimens, especially in cats and medium-to-large dogs. Home premedication remains simple, but a supervised trial dose and timing 1-2 hours before the trigger improve predictability.

The exact human immediate-release tablet is identifiable in a current regulator SPC and EU authorisation data; the 50 mg and 100 mg forms are not currently registered in Georgia. Veterinary use is off-label, but multiple species-specific controlled studies and professional guidelines support the active ingredient and route.

Small randomised studies support sedation and reduced transport/examination anxiety, including positive 50 mg and 5 mg/kg trials. Other small work found no examination-behaviour advantage at the tested time point, and current feline guidelines describe the evidence as conflicting; benefit is plausible but less secure than in dogs.

Small feline studies generally found sedation without serious short-term events, but they cannot define uncommon-event, repeated-use, geriatric, organ-disease or reproductive safety. Sedation, ataxia, gastrointestinal effects, cardiovascular change and serotonin syndrome remain relevant, especially with other serotonergic or CNS-depressant drugs.

A scored 50 mg tablet is easy to dispense and closely matches common single-dose study regimens, especially in cats and medium-to-large dogs. Home premedication remains simple, but a supervised trial dose and timing 1-2 hours before the trigger improve predictability.

The exact human drops are identifiable in a current regulator SPC and EU authorisation data; the 60 mg/ml form is also currently registered in Georgia, while the 25 mg/ml form is not. Veterinary use is off-label and the species studies used immediate-release oral trazodone rather than these exact liquid presentations.

Randomised controlled trials show meaningful reductions in selected stress and anxiety behaviours during veterinary visits, travel and shelter care, and observational evidence supports hospital use. Outcomes are not uniformly positive across every behaviour or postsurgical-confinement study, so it is a useful situational adjunct rather than a universally reliable sedative.

Oral veterinary studies generally found acceptable short-course tolerability, but sedation, ataxia, gastrointestinal effects, paradoxical excitation, tachycardia or hypotension and rare priapism remain relevant. Serotonin syndrome, additive CNS depression and QT-risk interactions require medication review; evidence is mostly from healthy or selected dogs.

The concentrated liquid may reduce administered volume in large dogs, but small feline or canine doses require very small, error-prone volumes. Confirm the measuring device, mg-to-ml conversion and excipients, and use a supervised trial dose before the target event.

The exact human drops are identifiable in a current regulator SPC and EU authorisation data; the 60 mg/ml form is also currently registered in Georgia, while the 25 mg/ml form is not. Veterinary use is off-label and the species studies used immediate-release oral trazodone rather than these exact liquid presentations.

Small randomised studies support sedation and reduced transport/examination anxiety, including positive 50 mg and 5 mg/kg trials. Other small work found no examination-behaviour advantage at the tested time point, and current feline guidelines describe the evidence as conflicting; benefit is plausible but less secure than in dogs.

Small feline studies generally found sedation without serious short-term events, but they cannot define uncommon-event, repeated-use, geriatric, organ-disease or reproductive safety. Sedation, ataxia, gastrointestinal effects, cardiovascular change and serotonin syndrome remain relevant, especially with other serotonergic or CNS-depressant drugs.

The concentrated liquid may reduce administered volume in large dogs, but small feline or canine doses require very small, error-prone volumes. Confirm the measuring device, mg-to-ml conversion and excipients, and use a supervised trial dose before the target event.

The exact 75 mg human prolonged-release product, active salt, equal thirds and current EU human authorisation are transparent, but veterinary use is unauthorised, the exact strength is only historically listed in Georgia and absent from the current in-force register, and no target-species study validates this release profile. The formulation-mismatch evidence gate caps this axis at 4.0.

Several controlled dog studies support immediate-release oral trazodone for selected situational stress roles, but no study validates prolonged-release Trittico 75 mg. Altered onset and peak exposure are central to pre-event efficacy, so ingredient evidence cannot be treated as exact-form evidence.

Short-course immediate-release dog studies are generally reassuring, but exact prolonged-release exposure and repeated-use safety are unknown. Sedation, ataxia, GI/paradoxical behaviour, hypotension, arrhythmia/QT risk, serotonin syndrome, seizure and rare priapism require selection and monitoring.

The tablet accurately divides into 25 mg thirds and home oral administration is feasible, correcting the former half-tablet metadata. However, it must not be crushed and no validated veterinary onset, timing or mg/kg schedule exists; immediate-release alternatives are more predictable for event-linked use.

The exact 75 mg human prolonged-release product, active salt, equal thirds and current EU human authorisation are transparent, but veterinary use is unauthorised, the exact strength is only historically listed in Georgia and absent from the current in-force register, and no target-species study validates this release profile. The formulation-mismatch evidence gate caps this axis at 4.0.

Small feline studies provide mixed support for immediate-release trazodone in pre-visit sedation/anxiolysis, but none validates prolonged-release Trittico 75 mg. The formulation transfer compounds already limited feline sample sizes and consistency.

Small immediate-release feline studies cannot define uncommon, prolonged-release, repeated, geriatric or organ-disease risk. Sedation/ataxia, GI or cardiovascular change, serotonin syndrome, seizure and interaction burden require conservative selection and monitoring.

Equal 25 mg thirds are more flexible than an indivisible 75 mg unit, but still coarse for many cats. No validated feline onset/timing exists for the prolonged-release profile, which is poorly matched to predictable pre-event dosing.

The exact human immediate-release tablet is identifiable in a current regulator SPC and EU authorisation data; the 50 mg and 100 mg forms are not currently registered in Georgia. Veterinary use is off-label, but multiple species-specific controlled studies and professional guidelines support the active ingredient and route.

Randomised controlled trials show meaningful reductions in selected stress and anxiety behaviours during veterinary visits, travel and shelter care, and observational evidence supports hospital use. Outcomes are not uniformly positive across every behaviour or postsurgical-confinement study, so it is a useful situational adjunct rather than a universally reliable sedative.

Oral veterinary studies generally found acceptable short-course tolerability, but sedation, ataxia, gastrointestinal effects, paradoxical excitation, tachycardia or hypotension and rare priapism remain relevant. Serotonin syndrome, additive CNS depression and QT-risk interactions require medication review; evidence is mostly from healthy or selected dogs.

The scored tablet permits 50 mg increments and is practical for many dogs, but is less flexible for cats and small dogs. Home premedication is simple; a supervised trial dose and timing 1-2 hours before the trigger improve predictability.

The exact human immediate-release tablet is identifiable in a current regulator SPC and EU authorisation data; the 50 mg and 100 mg forms are not currently registered in Georgia. Veterinary use is off-label, but multiple species-specific controlled studies and professional guidelines support the active ingredient and route.

Small randomised studies support sedation and reduced transport/examination anxiety, including positive 50 mg and 5 mg/kg trials. Other small work found no examination-behaviour advantage at the tested time point, and current feline guidelines describe the evidence as conflicting; benefit is plausible but less secure than in dogs.

Small feline studies generally found sedation without serious short-term events, but they cannot define uncommon-event, repeated-use, geriatric, organ-disease or reproductive safety. Sedation, ataxia, gastrointestinal effects, cardiovascular change and serotonin syndrome remain relevant, especially with other serotonergic or CNS-depressant drugs.

The scored tablet permits 50 mg increments and is practical for many dogs, but is less flexible for cats and small dogs. Home premedication is simple; a supervised trial dose and timing 1-2 hours before the trigger improve predictability.

The exact human prolonged-release product has verifiable Georgian and EU authorisation and transparent human regulatory status, but no veterinary authorisation or directly applicable target-species trial of this release profile was found. Immediate-release trazodone evidence cannot be assumed to establish onset or exposure for this formulation.

Controlled veterinary studies support immediate-release oral trazodone, not this prolonged-release presentation. Its altered release may change onset and peak effect, which are central to pre-visit and situational use; veterinary clinical efficacy for this exact formulation remains indirect.

Oral veterinary studies generally found acceptable short-course tolerability, but sedation, ataxia, gastrointestinal effects, paradoxical excitation, tachycardia or hypotension and rare priapism remain relevant. Serotonin syndrome, additive CNS depression and QT-risk interactions require medication review; evidence is mostly from healthy or selected dogs.

Once-daily human use does not translate into a validated veterinary pre-visit schedule. The scored tablet may be halved but must not be crushed, and 75 mg increments plus delayed release limit individual titration, especially in cats and small dogs.

The exact human prolonged-release product has verifiable Georgian and EU authorisation and transparent human regulatory status, but no veterinary authorisation or directly applicable target-species trial of this release profile was found. Immediate-release trazodone evidence cannot be assumed to establish onset or exposure for this formulation.

Controlled veterinary studies support immediate-release oral trazodone, not this prolonged-release presentation. Its altered release may change onset and peak effect, which are central to pre-visit and situational use; veterinary clinical efficacy for this exact formulation remains indirect.

Small feline studies generally found sedation without serious short-term events, but they cannot define uncommon-event, repeated-use, geriatric, organ-disease or reproductive safety. Sedation, ataxia, gastrointestinal effects, cardiovascular change and serotonin syndrome remain relevant, especially with other serotonergic or CNS-depressant drugs.

Once-daily human use does not translate into a validated veterinary pre-visit schedule. The scored tablet may be halved but must not be crushed, and 75 mg increments plus delayed release limit individual titration, especially in cats and small dogs.